Veracyte, Inc. , a leading cancer diagnostics company, today announced new data showing that its whole-genome sequencing (WGS)-based platform for minimal residual disease (MRD) testing detected cancer ...

DexCom (DXCM) announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NexGel Inc (NXGL – Research Report) and Dexcom ...

Shares of DexCom Inc. DXCM shed 1.93% to $72.13 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.12% to 5,712.20 and Dow ...

DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.

CGMs are transforming health tracking for non-diabetics, providing insights into glucose levels and influencing dietary choices and athletic performance.

AI-enhanced glucose monitoring provides predictive analytics and personalized insights for better blood sugar management.

Over the past six months, DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 8% to $74.17 per share. This run-up might have investors contemplating their ...

The "Electrocardiogram Monitoring Market Size, Share & Trend Analysis | Global | 2025-2031 | MedCore | Includes: ECG Monitor Market and ECG Electrode Market" report has been added to ...

The global US Remote Patient Monitoring Market, valued at US$14.15 billion in 2024, is forecasted to grow at a robust CAGR of 12.8%, reaching ...